1. Home
  2. ZGM vs ANTX Comparison

ZGM vs ANTX Comparison

Compare ZGM & ANTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ZGM

Zenta Group Company Limited Ordinary Shares

N/A

Current Price

$2.08

Market Cap

30.0M

ML Signal

N/A

Logo AN2 Therapeutics Inc.

ANTX

AN2 Therapeutics Inc.

HOLD

Current Price

$1.12

Market Cap

31.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ZGM
ANTX
Founded
2019
2017
Country
Macau
United States
Employees
N/A
N/A
Industry
Professional Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.0M
31.2M
IPO Year
2025
2022

Fundamental Metrics

Financial Performance
Metric
ZGM
ANTX
Price
$2.08
$1.12
Analyst Decision
Buy
Analyst Count
0
1
Target Price
N/A
$2.00
AVG Volume (30 Days)
25.0K
56.3K
Earning Date
02-08-2026
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
401.52
N/A
EPS
0.17
N/A
Revenue
$3,620,780.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$12.01
N/A
Revenue Growth
211.78
N/A
52 Week Low
$1.90
$1.01
52 Week High
$4.51
$1.55

Technical Indicators

Market Signals
Indicator
ZGM
ANTX
Relative Strength Index (RSI) N/A 50.17
Support Level N/A $1.03
Resistance Level N/A $1.15
Average True Range (ATR) 0.00 0.08
MACD 0.00 -0.00
Stochastic Oscillator 0.00 50.00

Price Performance

Historical Comparison
ZGM
ANTX

About ZGM Zenta Group Company Limited Ordinary Shares

Zenta Group Co Ltd is engaged in the provision of industrial park consultation services, business investment consultation services to clients through LIC, and sales of fintech products and services through LFT. Its industrial park consultation services are focused on the pre-development stage. Its business investment consultation services, offered through LIC, mainly focus on assisting clients to acquire stakes in specific investments, and it's normally in the form of equity ownership.

About ANTX AN2 Therapeutics Inc.

AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.

Share on Social Networks: